European Patent Grants for IMP731 Antibody
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- PRR Collaborates In New Clinical Trial For Imp321
- First Data From Phase IIb Clinical Trial of Imp321
- Prima BioMed Files U.S Shelf Registration Statement
- PRR Enters Agreement with Sydys to Advance CVac Program
- Japanese Patent Grants For IMP321 In Cancer
Later from Immutep
- Appendix 4E & 2016 Full Year Statutory Accounts
- S&P DJ Indices Announces March Quarterly Rebalance
- S&P DJ Indices Announces March Quarterly Review
- Wuxi & Prima sign MOU for strategic partnership
- Prima receives UK approval for AIPAC study
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep